secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001516551-24-000108
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience Q3 net loss $3.9M; cash $76.5M; nimacimab Phase 2 enrolling, interim data Q2 2025
--------------------------------------------------------------------------------

- Net loss $3.9M in Q3 2024 vs $24.9M loss in Q3 2023; decrease driven by absence of $21.2M in-process R&D acquisition expense.
- Cash and equivalents $76.5M including restricted $9.1M; court order allows release of $9M restriction before year-end.
- Phase 2 obesity trial for nimacimab enrolling; interim data Q2 2025, topline data Q4 2025.
- Preclinical DIO mouse model: nimacimab achieved up to 16% weight loss vs vehicle, with fat loss and lean mass preservation.
- Appointed Dr. Puneet Arora as Chief Medical Officer and Paul Grayson as Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000108/0001516551-24-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000108/skye-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001516551-24-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer